IBDEI2W0 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,48483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48483,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,48483,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,48483,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,48484,0)
 ;;=I69.292^^216^2407^36
 ;;^UTILITY(U,$J,358.3,48484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48484,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,48484,1,4,0)
 ;;=4^I69.292
 ;;^UTILITY(U,$J,358.3,48484,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,48485,0)
 ;;=I69.092^^216^2407^35
 ;;^UTILITY(U,$J,358.3,48485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48485,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,48485,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,48485,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,48486,0)
 ;;=I69.892^^216^2407^37
 ;;^UTILITY(U,$J,358.3,48486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48486,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,48486,1,4,0)
 ;;=4^I69.892
 ;;^UTILITY(U,$J,358.3,48486,2)
 ;;=^5007548
 ;;^UTILITY(U,$J,358.3,48487,0)
 ;;=I69.351^^216^2407^39
 ;;^UTILITY(U,$J,358.3,48487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48487,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
 ;;^UTILITY(U,$J,358.3,48487,1,4,0)
 ;;=4^I69.351
 ;;^UTILITY(U,$J,358.3,48487,2)
 ;;=^5007504
 ;;^UTILITY(U,$J,358.3,48488,0)
 ;;=I69.352^^216^2407^38
 ;;^UTILITY(U,$J,358.3,48488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48488,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
 ;;^UTILITY(U,$J,358.3,48488,1,4,0)
 ;;=4^I69.352
 ;;^UTILITY(U,$J,358.3,48488,2)
 ;;=^5007505
 ;;^UTILITY(U,$J,358.3,48489,0)
 ;;=I69.353^^216^2407^40
 ;;^UTILITY(U,$J,358.3,48489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48489,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
 ;;^UTILITY(U,$J,358.3,48489,1,4,0)
 ;;=4^I69.353
 ;;^UTILITY(U,$J,358.3,48489,2)
 ;;=^5007506
 ;;^UTILITY(U,$J,358.3,48490,0)
 ;;=I69.354^^216^2407^41
 ;;^UTILITY(U,$J,358.3,48490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48490,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
 ;;^UTILITY(U,$J,358.3,48490,1,4,0)
 ;;=4^I69.354
 ;;^UTILITY(U,$J,358.3,48490,2)
 ;;=^5007507
 ;;^UTILITY(U,$J,358.3,48491,0)
 ;;=I69.151^^216^2407^44
 ;;^UTILITY(U,$J,358.3,48491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48491,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right dominant side
 ;;^UTILITY(U,$J,358.3,48491,1,4,0)
 ;;=4^I69.151
 ;;^UTILITY(U,$J,358.3,48491,2)
 ;;=^5007441
 ;;^UTILITY(U,$J,358.3,48492,0)
 ;;=I69.152^^216^2407^42
 ;;^UTILITY(U,$J,358.3,48492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48492,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left dominant side
 ;;^UTILITY(U,$J,358.3,48492,1,4,0)
 ;;=4^I69.152
 ;;^UTILITY(U,$J,358.3,48492,2)
 ;;=^5007442
 ;;^UTILITY(U,$J,358.3,48493,0)
 ;;=I69.153^^216^2407^45
 ;;^UTILITY(U,$J,358.3,48493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48493,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right nondom side
 ;;^UTILITY(U,$J,358.3,48493,1,4,0)
 ;;=4^I69.153
 ;;^UTILITY(U,$J,358.3,48493,2)
 ;;=^5007443
 ;;^UTILITY(U,$J,358.3,48494,0)
 ;;=I69.154^^216^2407^43
 ;;^UTILITY(U,$J,358.3,48494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48494,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left nondom side
 ;;^UTILITY(U,$J,358.3,48494,1,4,0)
 ;;=4^I69.154
 ;;^UTILITY(U,$J,358.3,48494,2)
 ;;=^5007444
 ;;^UTILITY(U,$J,358.3,48495,0)
 ;;=I69.851^^216^2407^50
